Fortress Biotech, Inc. (FBIO) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
FBIO's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
FBIO Revenue Analysis (2013–2024)
As of February 28, 2026, Fortress Biotech, Inc. (FBIO) generated trailing twelve-month (TTM) revenue of $62.3 million, reflecting exceptional growth of +20.5% year-over-year. The most recent quarter (Q3 2025) recorded $17.6 million in revenue, up 7.4% sequentially.
Looking at the longer-term picture, FBIO's 5-year compound annual growth rate (CAGR) stands at +9.5%, indicating steady revenue expansion. The company achieved its highest annual revenue of $187.6 million in 2017.
Revenue diversification analysis shows FBIO's business is primarily driven by Qbrexza (49%), Accutane (38%), and Amzeeq (10%).
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), FBIO has underperformed the peer group in terms of revenue growth. Compare FBIO vs REGN →
Peer Comparison
Compare FBIO's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FBIOCurrent | $62M | +20.5% | +9.5% | -191.4% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $57.7M | -31.8% | $36.8M | 63.8% | $-110,379,000 | -191.4% |
| 2023 | $84.5M | +11.6% | $61.6M | 72.9% | $-142,342,000 | -168.4% |
| 2022 | $75.7M | +10.1% | $45.0M | 59.4% | $-203,564,000 | -268.8% |
| 2021 | $68.8M | +50.9% | $36.7M | 53.4% | $-188,541,000 | -274.1% |
| 2020 | $45.6M | +24.5% | $31.0M | 68.0% | $-94,270,000 | -206.7% |
| 2019 | $36.6M | +36.3% | $26.1M | 71.2% | $-110,819,000 | -302.5% |
| 2018 | $26.9M | -85.7% | $20.8M | 77.2% | $-119,997,000 | -446.4% |
| 2017 | $187.6M | +1038.3% | $26.4M | 14.1% | $-89,796,000 | -47.9% |
| 2016 | $16.5M | +1809.6% | $5.1M | 31.1% | $-65,710,000 | -398.7% |
| 2015 | $863K | - | $863K | 100.0% | $-50,531,000 | -5855.3% |
See FBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FBIO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare FBIO vs AGIO
See how FBIO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is FBIO's revenue growth accelerating or slowing?
FBIO revenue is accelerating at +20.5% year-over-year, exceeding the 5-year CAGR of +9.5%. TTM revenue reached $62M. Growth momentum has increased versus prior periods.
What is FBIO's long-term revenue growth rate?
Fortress Biotech, Inc.'s 5-year revenue CAGR of +9.5% reflects the sustained expansion pattern. Current YoY growth of +20.5% is above this long-term average.
How is FBIO's revenue distributed by segment?
FBIO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.